Lite Strategy (LITS) Non-Current Assets (2011 - 2026)
Lite Strategy (LITS) posted Non-Current Assets of $46.8 million for Q1 2026, down 35.0% on a QoQ basis from $72.0 million in Q4 2025.
Analysis
Lite Strategy (LITS) Non-Current Assets (2011 - 2026) Analysis & Trends
Lite Strategy has reported Non-Current Assets for 16 years, with the latest figure at $46.8 million in Q1 2026.
- On a quarterly basis, Non-Current Assets changed N/A year-over-year to $46.8 million in Q1 2026; TTM through Mar 2026 was $218.9 million, a 35733.06% increase from a year earlier, with the FY2024 full-year figure at $606000.0, down 95.44% from the prior year.
- Non-Current Assets was $46.8 million for Q1 2026 at Lite Strategy, down from $72.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $100.1 million in Q3 2025, with the low at $5000.0 in Q3 2024.
- Average Non-Current Assets over 5 years is $23.9 million, with a median of $13.1 million recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 99.96% in 2024, then jumped 2001920.0% in 2025.
- Over 5 years, Non-Current Assets stood at $14.2 million in 2022, then slipped by 12.63% to $12.4 million in 2023, then plunged by 99.96% to $5000.0 in 2024, then surged by 1440400.0% to $72.0 million in 2025, then plunged by 35.0% to $46.8 million in 2026.
- The last three Non-Current Assets figures came in at $46.8 million (Q1 2026), $72.0 million (Q4 2025), and $100.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 46.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 46.81 Mn |
| Dec 31, 2025 | 72.03 Mn |
| Sep 30, 2025 | 100.10 Mn |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 606,000.00 |
| Mar 31, 2024 | 11.89 Mn |
| Dec 31, 2023 | 12.37 Mn |
| Sep 30, 2023 | 12.83 Mn |
| Jun 30, 2023 | 13.28 Mn |
| Mar 31, 2023 | 13.70 Mn |
| Dec 31, 2022 | 14.15 Mn |
| Sep 30, 2022 | 14.68 Mn |
| Jun 30, 2022 | 10.71 Mn |
| Mar 31, 2022 | 10.96 Mn |
| Dec 31, 2021 | 8.74 Mn |
| Sep 30, 2021 | 8.99 Mn |
| Jun 30, 2021 | 9.28 Mn |
| Mar 31, 2021 | 9.56 Mn |
| Dec 31, 2020 | 9.85 Mn |
| Sep 30, 2020 | 10.08 Mn |